Virucidal Activity of the Drug «Thymogen®», a Nasal Dosed Spray, Against Human Respiratory Viruses In Vitro

Background. Respiratory syncytial virus (RSV) and parainfluenza virus together account for up to 40% of the pathogens causing acute respiratory infections in children and adults. RSV infection does not result in the development of stable immunity, which necessitates the search for effective methods of its drug-based prevention. The aim of the work was to study of the virucidal activity of the drug Thymogen®, a dosed nasal spray, against human respiratory viruses (parainfluenza virus and respiratory syncytial virus) in vitro. Material and methods. The virucidal effect of the drug Thymogen®, a dosed nasal spray, was studied in vitro on the Vero (ATCC CCL-81) cell culture in comparison with the drugs Hexoral® and Lizobact COMPLETE® against the parainfluenza virus and respiratory syncytial virus. The work was carried out in two stages: a study of the cytotoxicity of Thymogen® followed by a study of the virucidal effect at working range of drug concentrations of the drug. Results and discussion. The cytotoxicity assessment of the drug Thymogen®, a dosed nasal spray, allowed the use of a working range of drug concentrations of 0–63%. The virucidal activity of the drug Thymogen®, a dosed nasal spray, was revealed against the respiratory syncytial virus in vitro, starting with a drug concentration of 1.2%; and the parainfluenza virus, starting with a drug concentration of 0.4%. Conclusion. The obtained data may serve as a basis for conducting appropriate clinical studies on the use of the drug Thymogen®, a dosed nasal spray, in patients with acute respiratory viral infections, including respiratory syncytial virus and/or human parainfluenza virus as infectious agents.